Abstract
Background: There is still uncertainty concerning the risk of fetal malformation associated with the intake of various individual antiepileptic drugs in pregnant women. Objective: To assess the better-quality available evidence concerning the fetal hazards from exposure to antiepileptic drug monotherapy during human pregnancy. Method: Examination of the available English language literature, particularly that dealing with individual antiepileptic drugs used in monotherapy, in the larger case series with better-quality internal comparison data. Conclusions: There is reasonable evidence that valproate is a significant teratogen during therapeutic use in women; the other older antiepileptic drugs (phenobarbitone, phenytoin, carbamazepine) probably have some teratogenic potential, but less than valproate; the situation regarding the more recently marketed antiepileptic drugs is not yet clear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
